EA199900865A3 - Новые соединения дигидро- и тетрагидрохинолина, способ их получения и содержащие их фармацевтические составы - Google Patents

Новые соединения дигидро- и тетрагидрохинолина, способ их получения и содержащие их фармацевтические составы

Info

Publication number
EA199900865A3
EA199900865A3 EA199900865A EA199900865A EA199900865A3 EA 199900865 A3 EA199900865 A3 EA 199900865A3 EA 199900865 A EA199900865 A EA 199900865A EA 199900865 A EA199900865 A EA 199900865A EA 199900865 A3 EA199900865 A3 EA 199900865A3
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
optionally substituted
cycloalkyl
aryl
heterocycloalkyl
Prior art date
Application number
EA199900865A
Other languages
English (en)
Other versions
EA003272B1 (ru
EA199900865A2 (ru
Inventor
Патрик Казара
Жильбер Дорей
Пьер Лестаж
Бриан Локар
Original Assignee
Адир Э Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адир Э Компани filed Critical Адир Э Компани
Publication of EA199900865A2 publication Critical patent/EA199900865A2/ru
Publication of EA199900865A3 publication Critical patent/EA199900865A3/ru
Publication of EA003272B1 publication Critical patent/EA003272B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)

Abstract

Соединение общей формулы (I)где Rпредставляет собой атом водорода или группугде A является таким, как определено в описании,Rи R, каждый независимо, представляют собой алкил, циклоалкил, гетероциклоалкил, необязательно замещенный арил, необязательно замещенный гетероарил, циклоалкилалкил, гетероциклоалкилалкил, необязательно замещенный арилалкил, необязательно замещенный гетероарилалкил или необязательно замещенный аминоалкил илиRи Rвместе со связывающим их атомом углерода образуют циклоалкильную или моноциклическую гетероциклическую группу, замещенную или незамещенную,Rпредставляет собой атом водорода или группу, выбранную из необязательно замещенного алкила, необязательно замещенного алкенила и необязательно замещенного алкинила, или группу Q или - V-Q-, где V представляет собой группу алкилена, алкенилена или алкинилена и Q представляет собой необязательно замещенную циклоалкильную группу, необязательно замещенную арильную группу, необязательно замещенную гетероциклоалкильную группу или необязательно замещенную гетероарильную группу,Rи Rобразуют вместе связь или каждый представляет собой атом водорода,R, R, Rи Rкаждый независимо представляет собой атом водорода, атом галогена, алкильную группу, (C-C)циклоалкильную группу или группу -OW, где W является таким, как определено в описании.
EA199900865A 1998-10-23 1999-10-22 Производные дигидро- и тетрагидрохинолина, способ их получения и содержащие их фармацевтические составы EA003272B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9813306A FR2784988B1 (fr) 1998-10-23 1998-10-23 Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number Publication Date
EA199900865A2 EA199900865A2 (ru) 2000-04-24
EA199900865A3 true EA199900865A3 (ru) 2000-10-30
EA003272B1 EA003272B1 (ru) 2003-02-27

Family

ID=9531911

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900865A EA003272B1 (ru) 1998-10-23 1999-10-22 Производные дигидро- и тетрагидрохинолина, способ их получения и содержащие их фармацевтические составы

Country Status (20)

Country Link
US (1) US6350759B1 (ru)
EP (1) EP0995743B1 (ru)
JP (1) JP3159971B2 (ru)
KR (1) KR100421074B1 (ru)
CN (1) CN1255493A (ru)
AT (1) ATE236129T1 (ru)
AU (1) AU753044B2 (ru)
BR (1) BR9905587A (ru)
CA (1) CA2287046C (ru)
DE (1) DE69906445T2 (ru)
DK (1) DK0995743T3 (ru)
EA (1) EA003272B1 (ru)
ES (1) ES2196742T3 (ru)
FR (1) FR2784988B1 (ru)
NO (1) NO313590B1 (ru)
NZ (1) NZ500574A (ru)
PL (1) PL336139A1 (ru)
PT (1) PT995743E (ru)
SI (1) SI0995743T1 (ru)
ZA (1) ZA996667B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2001058889A1 (en) * 2000-02-11 2001-08-16 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US7144723B2 (en) * 2000-11-16 2006-12-05 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
KR100488444B1 (ko) * 2001-12-31 2005-05-11 한국과학기술연구원 퀴놀론 유도체 및 그 제조 방법
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
KR101049100B1 (ko) * 2002-08-02 2011-07-15 니리어스 파마슈티컬즈, 인코퍼레이션 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
AU2004226876A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
US8217072B2 (en) * 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
DE602004031614D1 (de) * 2003-06-20 2011-04-14 Nereus Pharmaceuticals Inc Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
US7166634B2 (en) 2004-01-23 2007-01-23 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
JP2007535559A (ja) 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
KR101282191B1 (ko) * 2004-12-03 2013-07-08 다나-파버 캔서 인스티튜트 인크. 신생물성 질환을 치료하는 조성물 및 방법
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
CN101460457B (zh) 2006-04-06 2012-07-18 尼瑞斯药品公司 Salinosporamide a及其类似物的全合成
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
TWI366565B (en) * 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
JP5247667B2 (ja) * 2008-12-05 2013-07-24 大塚製薬株式会社 医薬
KR101053329B1 (ko) * 2009-07-09 2011-08-01 삼성전기주식회사 세라믹 전자부품
CN102958919A (zh) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
CN103159676B (zh) * 2011-12-16 2015-07-15 卢忠林 一种式i化合物的制备方法
WO2013123658A1 (en) 2012-02-23 2013-08-29 Empire Technology Development Llc Azobenzene compounds with cholesterol group and their sunscreen compositions
CN117427077A (zh) 2014-09-14 2024-01-23 阿瓦尼尔制药股份有限公司 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
CA2978679A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
WO2017011399A1 (en) 2015-07-13 2017-01-19 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
IL260933B2 (en) 2016-02-08 2023-04-01 Beyondspring Pharmaceuticals Inc Preparations containing tocorsol or its analogues
CN107304184A (zh) * 2016-04-18 2017-10-31 诺华丝国际股份有限公司 用于从取代的1,2‑二氢喹啉除去污染物的方法
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
CA3052190A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
CN109553575B (zh) * 2017-09-27 2022-06-03 泰兴瑞泰化工有限公司 一种高纯乙氧基喹啉的吸附除杂方法
BR112020014960A2 (pt) 2018-01-24 2020-12-22 Beyondspring Pharmaceuticals, Inc. Composição e método para redução de trombocitopenia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331846A (en) * 1963-08-28 1967-07-18 Lilly Co Eli Metal catalyst process for converting alpha-amino-acetylenes to dihydroquinoline
IL51342A (en) * 1977-01-27 1980-11-30 Abic Ltd Ethoxyquin derivatives,their preparation and pharmaceutical and veterinary compositions comprising them
GB8816269D0 (en) * 1988-07-08 1988-08-10 Int Assn Of Fish Meal Manufact Compounds for use as anti-oxidants in fish meal/fish oil
US5688810A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
JPH09301953A (ja) * 1996-03-12 1997-11-25 Sanwa Kagaku Kenkyusho Co Ltd マロン酸ジアミド誘導体及びその用途

Also Published As

Publication number Publication date
BR9905587A (pt) 2001-12-11
CA2287046A1 (fr) 2000-04-23
CN1255493A (zh) 2000-06-07
FR2784988B1 (fr) 2002-09-20
DE69906445D1 (de) 2003-05-08
NZ500574A (en) 2000-08-25
ZA996667B (en) 2000-05-02
EA003272B1 (ru) 2003-02-27
ES2196742T3 (es) 2003-12-16
EA199900865A2 (ru) 2000-04-24
DE69906445T2 (de) 2004-04-08
JP3159971B2 (ja) 2001-04-23
KR100421074B1 (ko) 2004-03-04
DK0995743T3 (da) 2003-07-21
AU5600999A (en) 2000-05-04
KR20000029268A (ko) 2000-05-25
NO313590B1 (no) 2002-10-28
PL336139A1 (en) 2000-04-25
ATE236129T1 (de) 2003-04-15
EP0995743A1 (fr) 2000-04-26
NO995175L (no) 2000-04-25
JP2000128865A (ja) 2000-05-09
SI0995743T1 (en) 2003-08-31
NO995175D0 (no) 1999-10-22
FR2784988A1 (fr) 2000-04-28
US6350759B1 (en) 2002-02-26
AU753044B2 (en) 2002-10-03
EP0995743B1 (fr) 2003-04-02
PT995743E (pt) 2003-07-31
CA2287046C (fr) 2003-12-02

Similar Documents

Publication Publication Date Title
EA199900865A3 (ru) Новые соединения дигидро- и тетрагидрохинолина, способ их получения и содержащие их фармацевтические составы
AU5062996A (en) Novel pyridine compounds, processes for their preparation and the pharmaceutical compositions which contain them
NZ334954A (en) Substituted heterocycles as anti-tumor agents
AU2002239348A1 (en) Pyrazolopyridine derivatives
HU904956D0 (en) Process for producing benzopyrane derivatives and pharmaceutical preparatives containing such active agents
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
NZ236293A (en) 1-(alkyl or alkoxyalkyl)-4-phenyl piperidine-4-carboxylic acid amide derivatives; preparatory processes and pharmaceutical compositions
MY120237A (en) Method for the synthesis of quinoline derivatives
HUP9903783A2 (hu) Dihidro- és tetrahidrokinolinszármazékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
IE863374L (en) Indoles.
ES2001852A6 (es) Procedimiento para preparar un derivado de acido quinolocarboxilico
AU6288700A (en) Novel benzo[f]naphthyridine, preparation and compositions containing them
HUP0400436A2 (hu) Új triciklusos dihidrokinolin-vegyületek, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
MY131141A (en) N-benzyl-indoles, processes for their preparation and pharmaceutical compositions containing them.
HUT68064A (en) Process for preparing hexahydrobenzo[f]quinolinones
HU9802645D0 (en) New metalloproteinase inhibitors, process for producing them, and pharmaceutical compositions containing them
DK1155018T3 (da) Krystalmodifikation C af 8-cyano-1-cyclopropyl-7-(1S, 6S-2,8- diazabicyclo [4.3.0]nonan-8-yl) -6-fluor-1,4-dihydro-4-oxo-3-quinolin-carboxylsyre
ES2085234A1 (es) Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
ZA200003035B (en) Compounds of 7-oxo-2,3,7,14-tetrahydro-1H-benzo[B]-pyrano[3,2-H] acridin carboxylate, a process for their preparation and pharmaceutical compositions containing them.
IL109396A0 (en) Pyrido (1,2,3-DE) quinoxaline derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ES8302719A1 (es) Un procedimiento para preparar compuestos de cefem
HK1038741A1 (en) New substituted (dihydro) benzoxayine and (dihydro) benzothiazine compounds, a process for their preparation and pharmaceutical compositions containing them.
HK1024244A1 (en) 8h-thieno-(2,3-b)pyrrolizin-8-one compounds, a process for their preir preparation and pharmaceutical compositions containing them
IL147767A0 (en) Processes for the preparation of 2-arylvinyl alkyl ether and 1,4-diaryl-2-fluoro-2-butene compounds
AU1773497A (en) Novel 2,3-benzodiazepine derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU